Samsung Breaks New Ground with Mass Production of Industry’s Smallest 0.64μm-pixel Mobile Image Sensor
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced the industry’s first 0.64-micrometer (μm)-pixel image sensor, the 50-megapixel (Mp) Samsung ISOCELL JN1. Equipped with the latest pixel technologies such as enhanced ISOCELL 2.0, Smart-ISO and Double Super PDAF, the JN1 can capture more vivid images on the industry’s smallest 50Mp mobile sensor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005350/en/
Industry’s Smallest 0.64μm-Pixel Mobile Image Sensor, Samsung ISOCELL JN1 (Photo: Business Wire)
“Samsung’s advanced pixel technologies have once again pushed boundaries with the utmost precision to develop an image sensor with the industry’s smallest pixel size, yet with powerful performance. The new ISOCELL JN1 at 0.64μm will be able to equip tomorrow’s sleekest smartphones with ultra-high resolution mobile photographs,” said Duckhyun Chang, executive vice president of the sensor business at Samsung Electronics. “As we drive our commitment to innovation in pixel technologies, we will continue to bring a wide range of mobile image sensor offerings to the market.”
A new addition to Samsung’s high-resolution image sensor lineup, the JN1 employs ISOCELL 2.0 technology with added enhancements that improve light sensitivity by around 16-percent. For low-light environments, the sensor utilizes Samsung’s four-to-one pixel binning technology, Tetrapixel, which merges four adjacent 0.64μm-pixels into one big 1.28μm-pixel to quadruple light sensitivity for brighter 12.5Mp photographs.
With such advanced technologies all embedded in a small 1/2.76-inch optical format, the ISOCELL JN1 is the most versatile image sensor yet from Samsung. Through close collaboration with ecosystem partners, the JN1 is compatible with existing 1/2.8-inch products, allowing the sensor to be used for front-facing, ultra-wide or telephoto cameras, in addition to standard wide camera options. This means that users can take highly detailed selfies or group pictures in an amazing 50Mp resolution, as well as high-resolution video at up to 4K and high-zoom ratios. The smaller sensor can also reduce the height of the camera module by around 10-percent, minimizing the camera bulge for slimmer and more streamlined designs in next-generation smartphones.
For enhanced dynamic range, the ISOCELL JN1 comes with Smart-ISO, a technology that changes the conversion gain based on the environment’s illumination level. Smart-ISO uses Low ISO mode in bright settings to retain detail in the highlights, and High ISO in low-lit environments to reduce readout noise and generate excellent low-light performance. Using Smart-ISO, the JN1 also offers inter-scene HDR in mixed-light settings for optimum exposure levels derived from two separate readouts, from Low and High ISOs, that are merged to create a final image.
For faster auto-focus, the ISOCELL JN1 integrates improved Double Super PD. The previous Super PD technology used specially designed oval-shaped micro-lenses over two adjacent pixels arranged side by side to detect phases. Double Super PD features twice the density of pixels (1/16) used for phase detection than Super PD (1/32), enabling the same auto-focus performance even in environments with about 60-percent less illumination levels. For smooth crystal-clear videos, the image sensor supports up to 4K resolution video recording at 60 frames-per-second (fps) or full HD at 240fps.
The Samsung ISOCELL JN1 is currently in mass production.
* Editor's Note: Actual performance may vary depending on device and user environment.
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. Samsung continues to enhance its pixel isolation methods with ISOCELL Plus and the ISOCELL 2.0 technologies.
###
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005350/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)89-45578-1000
Email: sseg.comm@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release
Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
